The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

As China rises and other global cities aggressively court biotech talent, Massachusetts faces a "contracting moment" that has ...

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...

Wegovy in pill form -- helped patients lose 12% to 13%! Is Novo Nordisk stock a buy? Now factor in all the other good news Novo No ...

Wegovy is now positioned as the first and only GLP-1 treatment.

Recent federal and state developments have shifted the ground under medispas. The US Food and Drug Administration (FDA) ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Dr. Melanie Bone weighed in after one Ozempic user took to Reddit to share an unexpected outcome of taking the medication ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...